Skip to main content
. Author manuscript; available in PMC: 2021 Aug 16.
Published in final edited form as: J Vasc Surg. 2019 May 28;69(6 Suppl):3S–125S.e40. doi: 10.1016/j.jvs.2019.02.016

Table 11.2.

Bypass vs Angioplasty in Severe Ischaemia of the Leg (BASIL-2), Balloon vs Stenting in Severe Ischaemia of the Leg (BASIL-3), and Best Endovascular vs Best Surgical Therapy for Patients with Critical Limb Ischemia (BEST-CLI) trial end points

End points BASIL-2 and BASIL-3 BEST-CLI

Primary AFS MALE-free survival
Secondary Freedom from all-cause mortality
In-hospital and 30-day morbidity and mortality
MALE
MACE
Relief of ischemic pain
Psychological morbidity
HRQL: generic and disease-specific instruments
Reintervention and crossover intervention rates
Healing of tissue loss (ulcers, gangrene)
Extent and healing of minor amputations
Hemodynamic changes; absolute APs and TPs, ABI, TBI
HRQL (VascuQoL and EQ-5D)
Health economic analysis
Freedom from all-cause mortality
RAFS
Freedom from MALE and POD
AFS
Freedom from myocardial infarction
Freedom from stroke
Freedom from reinterventions (major and minor) in index leg
No. of reinterventions (major and minor) per limb salvaged
Freedom from hemodynamic failure
Freedom from clinical failure
Freedom from CLTI
HRQL (VascuQoL and EQ-5D)
Health economic analysis

ABI, Ankle-brachial index; AFS, amputation-free survival; APs, ankle pressures; CLTI, chronic limb-threatening ischemia; EQ-5D, EuroQol-5 Dimension questionnaire; HRQL, health-related quality of life; MACE, major adverse cardiac event; MALE, major adverse limb event; POD, perioperative death; RAFS, reintervention- and amputation-free survival; TBI, toe-brachial index; TPs, toe pressures; VascuQoL, Vascular Quality of Life questionnaire.

HHS Vulnerability Disclosure